TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19934423
Drug: ACLS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACLS with intravenous drug administration
Study: 19934423
Drug: ACLS without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACLS without intravenous drug administration
Study: 16476841
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (EPO), 10,000 U three times weekly s.c.
Study: 10677157
Drug: Heparin group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin group (maintaining a whole blood heparin concentration of 3 mg/kg)
Study: 24521107
Drug: Oxantel pamoate
Normalized name: OXANTEL PAMOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxantel pamoate (20 mg/kg) plus albendazole (400 mg)
Study: 20715734
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (target glycaemic control: 4.4 to 6.1 mmol/l)
Study: 20715734
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (target control: 10.0 to 11.1 mmol/l)
Study: 20715734
Drug: Glycaemic fluctuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycaemic fluctuation (mean difference between highest and lowest daily blood glucose)
Study: 18023151
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of parenteral veterinary preparation of ivermectin
Study: 18023151
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of oral albendazole 800 mg daily
Study: 10619727
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg) daily for 14 days
Study: 8949765
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron therapy alone or in combination with photons
Study: 7282596
Drug: Warfarin (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (0.01 mg/100 g, IP) with vitamin E (1000 units/kg IM for 7 days) in rats
Study: 26025128
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCS) - short-term oral prednisone bursts during acute asthma exacerbations
Study: 14747807
Drug: Delayed-release acetaminophen
Normalized name: acetaminophen Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release acetaminophen preparation (75 mg/kg) with whole bowel irrigation
Study: 11878526
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of 7.5 mg ml(-1) ropivacaine (18.75 mg)
Study: 11878526
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of 10 mg ml(-1) ropivacaine (25 mg)
Study: 9492256
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of itraconazole 40‐mg/mL oral suspension
Study: 9492256
Drug: Four 100‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 100‐mg itraconazole capsules
Study: 9492256
Drug: Hydroxyitraconazole from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyitraconazole from the suspension
Study: 9492256
Drug: Hydroxyitraconazole from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyitraconazole from the capsules
Study: 2839280
Drug: Adriamycin 60
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin 60 to 75 mg/m2 at 3-week intervals
Study: 24814388
Drug: Mericitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) plus ribavirin (1000/1200 mg/day) for 24 weeks
Study: 24814388
Drug: Mericitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) without ribavirin (Arm B) for 24 weeks
Study: 23911183
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy with threshold suspend
Study: 21744200
Drug: Handpiece removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handpiece removal of mini-implants
Study: 21744200
Drug: Manual removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual removal of mini-implants
Study: 21744200
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local anesthetic injection
Study: 16484892
Drug: Glibenclamide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (20 mg)
Study: 14574783
Drug: High-dose paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose paracetamol (6 g daily)
Study: 9411418
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (mean daily dose 18 +/- 8 U)
Study: 1551536
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 micrograms single dose)
Study: 1551536
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 micrograms single dose and 150 micrograms/day for 1 week)
Study: 25046070
Drug: Desloratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (5 mg/d)
Study: 17393438
Drug: Gabapentin (1,200-2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,200-2,400 mg/day)
Study: 12049678
Drug: Esmolol (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (24-hour infusion starting 6-18 hours after CABG at an average dose of 67 +/- 7 microg/kg/min)
Study: 12049678
Drug: Oral beta-blockers
Normalized name: beta carotene Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta-blockers only (starting on postoperative day 1)
Study: 4561679
Drug: Bromhexine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine (24 mg or 48 mg daily)
Study: 22092124
Drug: Triple prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple prophylaxis (dexamethasone 8 mg IV, ondansetron 4 mg IV, droperidol 0.625 mg IV)
Study: 16340950
Drug: Iron plus
Normalized name: Nu-Iron Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron plus iodine (190 mg iodine + 300 mg ferrous sulphate 5 times/week, n=24)
Study: 16340950
Drug: Iron (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (300 mg ferrous sulphate 5 times/week, n=23)
Study: 16340950
Drug: Iodine (190
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine (190 mg iodine, n=25)
Study: 9121326
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus ofloxacin administered daily for 4 weeks
Study: 3721646
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin 100 IU i.m. daily for 30 days
Study: 30138966
Drug: Adiponectin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin (20 μg/ml for 30 minutes)
Study: 30427152
Drug: Decrease of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease of ionized calcium content (till 0.32 mmole/l) in venous blood
Study: 30427152
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of lactate content (up to 4.1 mmole/l) in venous blood
Study: 24415567
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control (pseudo‐placebo monotherapy)
Study: 7853417
Drug: Etoposide and
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide and cisplatin plus twice-daily chest radiotherapy (n = 54)
Study: 7853417
Drug: Standard-dose etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose etoposide plus cisplatin (n = 46)
Study: 7853417
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide plus cisplatin (n = 44)
Study: 7853417
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose etoposide plus cisplatin for poor-risk patients (n = 25)
Study: 31162017
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (6 months deferred)
Study: 21574777
Drug: Creatine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g·day(‐1) for 1 week and 5 g·day(‐1) thereafter)
Study: 11378339
Drug: Chemotherapy (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (doxorubicin 50 mg/m² i.v. bolus and ifosfamide 5 g/m² 24 h infusion)
Study: 11378339
Drug: Chemotherapy (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (doxorubicin and ifosfamide)
Study: 8357473
Drug: Sublingual specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual specific immunotherapy with purified and standardised allergen (Stallergenes '5-grass pollen')
Study: 3511392
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg 5 X in 30 h)
Study: 22837545
Drug: Daily life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily life activities (Control)
Study: 29540336
Drug: Ilaparazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaparazole 10 mg QD
Study: 29540336
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg QD
Study: 25005651
Drug: Postoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotic treatment with amoxicillin plus clavulanic acid (2 g, 3 times a day for 5 days)
Study: 25005651
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotics (nontreatment group)
Study: 25005651
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (antibiotic and nontreatment)
Study: 17974932
Drug: Self-management cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management cognitive behavior therapy
Study: 16387596
Drug: Omalizumab (0.016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (0.016 mg/kg/IgE [IU/mL]/mo) plus immunotherapy
Study: 16387596
Drug: Omalizumab plus
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab plus immunotherapy
Study: 16387596
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus immunotherapy
Study: 31061282
Drug: Na restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na restriction (NaCl: 6 g/d)
Study: 31061282
Drug: Control (NaCl:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (NaCl: 12 g/d)
Study: 23912197
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling combined with autologous conditioned plasma (ACP) injection
Study: 12078910
Drug: Early complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early complete response (ECR) patients after initial cycles of chemotherapy
Study: 12078910
Drug: Shortened treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened treatment in ECR patients (randomized Swedish trial)
Study: 12078910
Drug: Anthracyclines plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracyclines plus alkylating agents in children who failed to reach ECR (French MDH 90 trial)
Study: 9621488
Drug: Carboplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (100 mg/m2 at 7 and 21 days) with 148 MBq 89Sr
Study: 9621488
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2 in two administrations) with 148 MBq 89Sr
Study: 62265
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (MOPP: mustine hydrochloride, vincristine, procarbazine, and prednisone)
Study: 62265
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (MOPP)
Study: 11137283
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ritanserin for 4 weeks
Study: 9392620
Drug: Continuous-infusion BSO
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion BSO alone
Study: 9392620
Drug: BSO plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSO plus melphalan (15 mg/m2)
Study: 7639365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fentanyl and clonidine
Study: 21154196
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) infused at a constant rate of 2 mIU/ml from -15 to 60 min before insulin administration
Study: 14564551
Drug: Modified angiographic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified angiographic protocol (127 patients); 20 mL iodinated contrast, digital subtraction fluoroscopy for 60 sec.
Study: 10625720
Drug: Clomethiazole (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole (75 mg/kg intravenous infusion for 24 hours)
Study: 1590670
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin therapy
Study: 2859871
Drug: Adimolol 25
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adimolol 25 mg
Study: 2859871
Drug: Adimolol 600
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adimolol 600 mg
Study: 2859871
Drug: Adimolol 400
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adimolol 400 mg
Study: 2859871
Drug: Labetalol 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 800 mg
Study: 29678756
Drug: D&C plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: D&C plus NCH gel application (NCH gel group)
Study: 27626473
Drug: LDE-paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE-paclitaxel (175 mg/m2, intravenous administration, 3/3 weeks for 6 cycles)
Study: 25197811
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg) in the morning
Study: 25197811
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg) in the evening
Study: 17664376
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 or 40 mg, depending on age, continued after a previous placebo-controlled study for an average treatment period of 4.5 years.
Study: 16236186
Drug: Haem iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haem iron preparation
Study: 12473512
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral therapies
Study: 10209080
Drug: Ephedrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (50 mg thrice daily)
Study: 7609291
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 50 mg plus continuous epidural infusion with buprenorphine and bupivacaine
Study: 7609291
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion with buprenorphine and bupivacaine
Study: 318971
Drug: Fosfomycin 2
Normalized name: fosfomycin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin 2 g daily in four divided doses for 28 days
Study: 31021036
Drug: facilitated subcutaneous
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: facilitated subcutaneous immunoglobulin (fSCIG)
Study: 31021036
Drug: conventional subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional subcutaneous immunoglobulin (cSCIG)
Study: 27592520
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music three days a week for 8 weeks)
Study: 21792546
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (control group) with monthly social work contact
Study: 19873915
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Methycobal and Vitamin B1 (medication group)
Study: 17878129
Drug: Breast Cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast Cancer Education Intervention (BCEI) delivered in three face‐to‐face sessions and five monthly follow‐up sessions (three by telephone and two in person)
Study: 17878129
Drug: Wait control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait control group receiving four monthly attention control telephone calls and the BCEI at month 6
Study: 10690889
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group A (4 IU/m2 x day)
Study: 10690889
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group B (4 IU/m2 x day for the first year, then 6 IU/m2 x day)
Study: 10690889
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group C (4 IU/m2 x day for the first year, 6 IU/m2 x day for the second year, then 8 IU/m2 x day)
Study: 10690889
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment group C1 (7-year data from group C)
Study: 10690889
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (mean duration 85.3 months)
Study: 8360391
Drug: Anthelmintic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelmintic treatment (Oxantel-Pyrantel; Quantrel) for 22 months
Study: 8360391
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (children who declined treatment)
Study: 2875439
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: no treatment
Study: 20830502
Drug: Vandetanib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (100 mg once daily) plus docetaxel (100 mg/m² IV every 21 days)
Study: 20830502
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus docetaxel (100 mg/m² IV every 21 days)
Study: 19459523
Drug: Histamine-2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 receptor antagonists (H2RA)
Study: 15562020
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg testosterone enanthate weekly
Study: 15562020
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg testosterone enanthate weekly
Study: 15562020
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg testosterone enanthate weekly
Study: 15562020
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg testosterone enanthate weekly
Study: 15562020
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg testosterone enanthate weekly
Study: 12244484
Drug: Medium-molecular-weight heparin
Normalized name: chitosan medium molecular weight (200-800 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-molecular-weight heparin (MMWH)
Study: 10443094
Drug: Xylocaine injection
Normalized name: Xylocaine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocaine injection at the gastrocnemius trigger point (TrP)
Study: 10443094
Drug: Oral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinine sulfate 300 mg
Study: 7603215
Drug: Ganciclovir (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (6 mg/kg body weight per day intravenously from postoperative day 1 to day 30, then 6 mg/kg per day Monday through Friday until day 100)
Study: 7603215
Drug: Acyclovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (10 mg/kg intravenously every 8 h from postoperative day 1 to day of discharge, then 800 mg orally four times a day until day 100)
Study: 1695049
Drug: Cisplatin (DDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (DDP) in combination with Adriamycine (ADM) and Cyclophosphamid (CTX)
Study: 23786282
Drug: SIT (Specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (Specific Immunotherapy)
Study: 15531661
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plant sterols and exercise
Study: 9272403
Drug: Moxonidine 0.4
Normalized name: moxonidine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.4 mg once daily with lorazepam
Study: 23665885
Drug: Heparin filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin filling
Study: 22172428
Drug: Gold kiwifruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold kiwifruit (4 kiwifruit daily)
Study: 22172428
Drug: Banana (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banana (2 bananas daily)
Study: 20420510
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (180 microg weekly for 12 weeks)
Study: 17394626
Drug: Ibuprofen-foam dressing
Normalized name: ibuprofen Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-foam dressing
Study: 10988044
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g taken 30 min before HSG
Study: 8841797
Drug: S-adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAMe) 1000 mg/day i.m.
Study: 8841797
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 450 mg/day
Study: 6715724
Drug: Flurbiprofen, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen, 75 mg
Study: 6715724
Drug: Chlorpheniramine, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine, 6 mg
Study: 31791370
Drug: Healthy lifestyle
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy lifestyle modification based on traditional Chinese medicine (TCM)